Inmune Bio (INMB) Return on Assets (2019 - 2026)

Inmune Bio (INMB) posted Return on Assets of 0.02% for Q1 2026, up 12.47% sequentially from 0.02% in Q4 2025, and up 4.0% YoY from 0.02% in Q1 2025.

Inmune Bio (INMB) Return on Assets (2019 - 2026) Analysis & Trends

Inmune Bio has reported Return on Assets for 8 years, with the latest figure at 0.02% in Q1 2026.

Quarterly Return on Assets rose 4.0% year-over-year to 0.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (up 4.0% YoY) and the FY2025 annual result came in at 0.02%, down 1.0% from the prior year.
Return on Assets advanced to 0.02% in Q1 2026 per INMB's latest filing, from 0.02% in the prior quarter.
Over five years, Return on Assets peaked at 0.01% in Q3 2023 and troughed at 0.08% in Q2 2023.
A 5-year average of 0.03% and a median of 0.02% in 2025 frame the typical range for Return on Assets.
The widest YoY moves for Return on Assets: up 6 bps in 2023, down 7 bps in 2023.
Over 5 years, Return on Assets stood at 0.07% in 2022, then surged by 91 bps to 0.01% in 2023, then plunged by 687 bps to 0.05% in 2024, then soared by 63 bps to 0.02% in 2025, then rose by 12 bps to 0.02% in 2026.
According to Business Quant data, Return on Assets over the past three periods registered 0.02%, 0.02%, and 0.05% for Q1 2026, Q4 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	139.59 Bn	131.73 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.21 Bn	78.22 Bn	3.93 Bn	0.00%
3	Argenx Se	65.65 Bn	60.47 Bn	1.37 Bn	-
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn	0.00%
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	0.00%
7	BioNTech SE	27.90 Bn	9.51 Bn	668.28 Mn	0.00%
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	0.00%
10	Inmune Bio	61.19 Mn	42.77 Mn	-	-0.01%

Download Data